Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zhuhai Trinomab Pharmaceutical Co PB Ratio?
Zhuhai Trinomab Pharmaceutical CoSHSE:688806 -4.38%2 PB Ratio is 78.19 as of Sep. 10, 2026, which is 19% below its 10-year median of 96.45. GuruFocus rates SHSE:688806 with a GF Score™ of 2/100. The stock has 7 warning signs investors should review. Among 919 Drug Manufacturers companies, Zhuhai Trinomab Pharmaceutical Co ranks worse than 99.56% on this metric.
SHSE:688806'
s PB Ratio Range Over the Past 10 Years
Min: 76.74 Med: 96.45 Max: 106.38
Current: 76.74
During the past 4 years, Zhuhai Trinomab Pharmaceutical Co's highest PB Ratio was 106.38. The lowest was 76.74. And the median was 96.45.
SHSE:688806's PB Ratio is ranked worse than 99.56% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs SHSE:688806: 76.74
During the past 12 months, Zhuhai Trinomab Pharmaceutical Co's average Book Value Per Share Growth Rate was -74.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -53.70% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhuhai Trinomab Pharmaceutical Co was -53.70% per year. The lowest was -53.70% per year. And the median was -53.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhuhai Trinomab Pharmaceutical Co PB Ratio Related Terms
Zhuhai Trinomab Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhuhai Trinomab Pharmaceutical Co PB Ratio Chart
Zhuhai Trinomab Pharmaceutical Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
0.00
Zhuhai Trinomab Pharmaceutical Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
0.00
SHSE:688806 vs ZTS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhuhai Trinomab Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhuhai Trinomab Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhuhai Trinomab Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zhuhai Trinomab Pharmaceutical Co's PB Ratio falls into.
Zhuhai Trinomab Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) has a PB Ratio of 78.19 as of Sep. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhuhai Trinomab Pharmaceutical Co and its competitors. This is 19% below median its historical median of 96.45. Over the past decade, Zhuhai Trinomab Pharmaceutical Co's PB Ratio has ranged from 76.74 to 106.38. According to the industry distribution chart, Zhuhai Trinomab Pharmaceutical Co ranks #915 out of 919 companies in the Drug Manufacturers industry, placing it in the top 99.6%.
Is Zhuhai Trinomab Pharmaceutical Co's PB Ratio too high?
Zhuhai Trinomab Pharmaceutical Co's current PB Ratio of 78.19 is 19% below median its 10-year median of 96.45. Over the past 10 years, this metric has ranged from a low of 76.74 to a high of 106.38. The Drug Manufacturers industry median PB Ratio is 1.96. Zhuhai Trinomab Pharmaceutical Co's value of 78.19 is 3889.3% above this industry median. Based on the distribution chart, Zhuhai Trinomab Pharmaceutical Co ranks #915 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhuhai Trinomab Pharmaceutical Co has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does Zhuhai Trinomab Pharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhuhai Trinomab Pharmaceutical Co ranks #915 out of 919 companies for PB Ratio. This places Zhuhai Trinomab Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.96. Zhuhai Trinomab Pharmaceutical Co's value of 78.19 is 3889.3% above this benchmark. Historically, Zhuhai Trinomab Pharmaceutical Co's own PB Ratio has ranged from 76.74 to 106.38 over the past decade. While the company's 10-year median is 96.45 vs. the industry median of 1.96, Zhuhai Trinomab Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhuhai Trinomab Pharmaceutical Co's current PB Ratio of 78.19 is 3889.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhuhai Trinomab Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhuhai Trinomab Pharmaceutical Co's current PB Ratio is 78.19, which is 19% below median its own 10-year median of 96.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhuhai Trinomab Pharmaceutical Co stock overvalued right now?
Zhuhai Trinomab Pharmaceutical Co (SHSE:688806) has a current PB Ratio of 78.19. The current PB Ratio is 78.19, which is 19% below median its 10-year median of 96.45 and 3889.3% above the Drug Manufacturers industry median of 1.96. Zhuhai Trinomab Pharmaceutical Co's overall GF Score™ is 2/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhuhai Trinomab Pharmaceutical Co (SHSE:688806), the current PB Ratio is 78.19 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688806 has been successfully added to your 
